Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Sandborn

Showing results (121-130 of 186) with videos related to

Pageof 19
Sort By:
The American Journal of Gastroenterology|December 1, 1995
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosisB J Zins, W J Sandborn, C R Penna, et al.
Alimentary Pharmacology & Therapeutics|December 14, 1999
A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitisL J Egan, W J Sandborn, W J Tremaine, et al.
Alimentary Pharmacology & Therapeutics|November 14, 1997
Nicotine enemas for active ulcerative colitis--a pilot studyJ T Green, G A Thomas, J Rhodes, et al.
The Journal of Biological Chemistry|September 3, 1999
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activityL J Egan, D C Mays, C J Huntoon, et al.
The American Journal of Gastroenterology|July 14, 2000
Early measles virus infection is associated with the development of inflammatory bowel diseaseD S Pardi, W J Tremaine, W J Sandborn, et al.
Gastroenterology|June 1, 1994
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitisW J Sandborn, W J Tremaine, K W Schroeder, et al.
Alimentary Pharmacology & Therapeutics|September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitisB Jharap, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|March 20, 2010
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's diseaseR Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2015
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseM Rosario, N L Dirks, M R Gastonguay, et al.
Clinical Pharmacology and Therapeutics|March 1, 1997
Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitisJ T Green, G A Thomas, J Rhodes, et al.
Pageof 19

Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
The American Journal of Gastroenterology|December 1, 1995
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosisB J Zins, W J Sandborn, C R Penna, et al.
Alimentary Pharmacology & Therapeutics|December 14, 1999
A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitisL J Egan, W J Sandborn, W J Tremaine, et al.
Alimentary Pharmacology & Therapeutics|November 14, 1997
Nicotine enemas for active ulcerative colitis--a pilot studyJ T Green, G A Thomas, J Rhodes, et al.
The Journal of Biological Chemistry|September 3, 1999
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activityL J Egan, D C Mays, C J Huntoon, et al.
The American Journal of Gastroenterology|July 14, 2000
Early measles virus infection is associated with the development of inflammatory bowel diseaseD S Pardi, W J Tremaine, W J Sandborn, et al.
Gastroenterology|June 1, 1994
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitisW J Sandborn, W J Tremaine, K W Schroeder, et al.
Alimentary Pharmacology & Therapeutics|September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitisB Jharap, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|March 20, 2010
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's diseaseR Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2015
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseM Rosario, N L Dirks, M R Gastonguay, et al.
Clinical Pharmacology and Therapeutics|March 1, 1997
Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitisJ T Green, G A Thomas, J Rhodes, et al.
Pageof 19